Botanix Pharmaceuticals Ltd
BOT
Company Profile
Business description
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Contact
41 - 47 Colin Street
Suite 3
West PerthWA6005
AUST: +61 865552945
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
1
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
stocks
Wide moat airport share steps up its investments
Profits flatten as airport ramps up redevelopment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,307.30 | 0.20 | -0.00% |
| CAC 40 | 8,484.43 | 31.34 | 0.37% |
| DAX 40 | 26,136.56 | 153.52 | 0.59% |
| Dow JONES (US) | 53,277.01 | 517.80 | 0.98% |
| FTSE 100 | 10,816.56 | 68.40 | 0.64% |
| HKSE | 25,496.32 | 513.14 | -1.97% |
| NASDAQ | 26,180.46 | 113.29 | 0.43% |
| Nikkei 225 | 65,508.44 | 507.92 | -0.77% |
| NZX 50 Index | 13,881.88 | 90.78 | -0.65% |
| S&P 500 | 7,674.37 | 33.21 | 0.43% |
| S&P/ASX 200 | 9,094.10 | 0.90 | 0.01% |
| SSE Composite Index | 3,869.43 | 35.77 | -0.92% |